#USA #Charlotte #Immunic #Vidofludimus Calcium #CMSC Annual Meeting

Introduction

Immunic, Inc., a prominent player in the biotechnology landscape, has recently shed light on additional compelling data regarding its lead investigational drug, Vidofludimus Calcium, during the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting held from May 27 to 29 in Charlotte, North Carolina. This late-breaking presentation serves to underscore the drug's promising safety profile and its therapeutic potential in patients suffering from Progressive Multiple Sclerosis (PMS).

Presentation Highlights

During the conference, Immunic presented a late-breaking poster along with two additional posters from its Phase 2 CALLIPER trial, focusing on Vidofludimus Calcium, which is noted for its unique mechanism that potentially combines neuroprotective, anti-inflammatory, and anti-viral effects. The CEO of Immunic, Dr. Daniel Vitt, expressed optimism regarding the newly presented data, stating that it enhances the understanding of Vidofludimus Calcium's efficacy in managing multiple sclerosis (MS) symptoms.

The most notable aspect of these presentations was the introduction of a new analytical framework for assessing disability change, capturing both progression and remission within the same model. This innovative approach aims to offer a more comprehensive view of the drug's effectiveness compared to traditional methods that typically focus solely on deterioration.

Key Findings from the CALLIPER Trial

Unified Statistical Analyses

The late-breaking poster presented by James Myles, Immunic's Global Head of Biostatistics, introduced a novel statistical endpoint for evaluating Confirmed Disability Change (CDC) in PMS patients. This analysis employs a unified framework that captures both confirmed disability worsening (CDW) and improvement (CDI) effectively. Utilizing various statistical modeling techniques, the results consistently favored Vidofludimus Calcium over placebo, suggesting this new method may improve the evaluation of potential neuroprotective effects and could enhance the statistical power in future clinical trials.

Patient-Reported Outcomes

Another significant aspect of Immunic’s presentation was centered on patient-reported outcomes led by Dr. Julie Korich. The data illustrated that patients on Vidofludimus Calcium experienced similar levels of depressive thoughts compared to those on placebo, indicating no negative impact on their psychological wellbeing throughout the treatment period of up to 120 weeks. Notably, the results indicated a greater reported effectiveness of treatment among participants receiving Vidofludimus Calcium, enhancing their overall satisfaction and perceived improvements.

Safety Profile

Lastly, Dr. Alex Lublin discussed the safety and tolerability profile of Vidofludimus Calcium, revealing comparable rates of treatment-emergent adverse events (TEAEs) for both the treatment and placebo groups. Most reported side effects included headaches and urinary infections, which occurred at similar rates, further supporting the drug’s favorable safety profile. The consistency of adverse events and the low rates of serious side effects underscore the potential for Vidofludimus Calcium as a viable treatment option.

Conclusion

The data presented at the CMSC Annual Meeting holds significant promise for Vidofludimus Calcium in the treatment of Progressive Multiple Sclerosis. As Immunic continues with its clinical trials, these promising findings not only bolster confidence in the drug’s efficacy but also illuminate a path toward potentially improving the quality of life for patients battling this challenging illness. Future research will no doubt shed more light on the full therapeutic capabilities of Vidofludimus Calcium, but for now, these results lay a robust foundation for its ongoing development.

For more detailed information, access the full presentations on Immunic’s official website under the Events and Presentations section.